Press Releases
Date picker
Category
Results per page
Kancera provides operational update of the Fractalkine and ROR projects
Kancera reports that the Fractalkine antagonist KAN0440567 is able to eliminate pain resulting from inflammation of the pancreas and that the ROR inhibitor KAN0439834 has been shown to effectively kill…
Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016
Regulatory
The period January to March 2016 in brief R&D expenses for the period amounted to SEK 4.2m (SEK 4.2m). Operating income for the period amounted to SEK -5.1m (SEK 4.9m).…
Kancera acquires the Fractalkine project
Due to positive efficacy data in disease models of cancer and pain, Kancera's Board of Directors has decided to exercise the exclusive option to acquire the Fractalkine project.
Kancera provides operational update of the ROR and PFKFB3 projects
Kancera reports that ROR inhibitors have been tested against human triple negative breast cancer transferred to zebrafish. The experiments showed that Kancera's small molecule ROR inhibitors are able to both…
Kancera provides operational update of the ROR and Fractalkine projects
Kancera reported that the company has developed a new series of ROR inhibitors that show improved pharmaceutical properties which will allow preclinical studies of their effect on e.g. solid tumors.…
Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015
Regulatory
The period January to December 2015 and the fourth quarter 2015 in brief R&D expenses for the period amounted to SEK 20.4m (SEK 13.7m) of which the fourth quarter constituted…
Kancera provides operational update of the small molecule patent portfolio
Kancera's patent covering small molecule inhibitors of PFKFB3 has been approved in the United States. Further, a patent application covering new chemical series in the HDAC6 project has been filed…
Kancera provides operational update
Kancera hereby provides an operational update on the PFKFB3 and HDAC6 projects as well as the EU-funded epigenetically targeted parasitic project A-PARADDISE.
Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.
Regulatory
The period January to September 2015 and the third quarter 2015 in brief R&D expenses for the period amounted to SEK 12.1m (SEK 9.6m) of which the third quarter constituted…
Kancera provides operational update on the ROR and Fractalkine projects
In connection with a meeting arranged by the Swedish Shareholders' Association in Malmö on September 30, Kancera provides an operational update on the ROR and Fractalkine projects.